Angiostatic activity of human plasminogen fragments is highly dependent on glycosylation

Cancer Science

Volumn 101, Issue 2, 2010, Pages 453-459

  Santos, Ivan Carlos ^a   Silbiger, Vivian Nogueira ^b   Higuchi, Débora Ayame ^b   Gomes, Maria Aparecida ^a   Barcelos, Lucíola Silva ^a   Teixeira, Mauro Martins ^a   Lopes, Mirian Teresa Paz ^a   Cardoso, Valbert Nascimento ^a   Lima, Mercia Paula ^a   Araujo, Ronaldo Carvalho ^c   Pesquero, João Bosco ^c   Pesquero, Jorge Luiz ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSIDADE DE MOGI DAS CRUZES   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN KINT[3-4]; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL INFILTRATION; CONTROLLED STUDY; DEGLYCOSYLATION; DRUG DOSE COMPARISON; GENE EXPRESSION; HEMOGLOBIN BLOOD LEVEL; KRINGLE DOMAIN; MALE; MELANOMA B16; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; SEQUENCE ANALYSIS;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANIMALS; GLYCOSYLATION; HUMANS; INTEGRIN ALPHAVBETA3; MALE; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PLASMINOGEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 75649152099     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01403.x     Document Type: Article

References (39)

1. Griffioen AW, Molema G. Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000, 52:237-68.
2. Folkman J. Seminars in medicine of the Beth Israel hospital, Boston: clinical applications of research on angiogenesis. N Engl J Med 1995, 333:1157-63.
3. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987, 235:442-7.
4. Colville-Nash PR, Alan CAS, Appleton I, Brown JR, Seed MP, Willoughby DA. The pharmacological modulation of angiogenesis in chronic granulomatous inflammation. J Pharmacol Exp Ther 1995, 274:1463-72.
5. Montag M, Dyckhoff G, Lohr J. Angiogenic growth factors in tissue homogenates of HNSCC: expression pattern, prognostic relevance, and interrelationships. Cancer Sci 2009, 100:1210-8.
6. Klagsbrun M, Moses MA. Molecular angiogenesis. Chem Biol 1999, 6:217-24.
7. Yanagi K, Onda M, Uchida E. Effect of angiostatin on liver metastasis of pancreatic cancer in hamsters. Cancer Sci 2000, 91:723-30.
8. Kim CK, Hong SH, Joe YA, Shim B, Lee S, Hong Y. The recombinant kringle domain of urokinase plasminogen activator inhibits in vivo malignant glioma growth. Cancer Sci 2007, 98:253-8.
9. Freeman MR, Schneck FX, Gagnon ML. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: A potential role for T cells in angiogenesis. Cancer Res 1995, 55:4140-5.
10. Cao Y, Ji RW, Davidson D. Kringle domains of human angiostatin. J Biol Chem 1996, 46:29461-7.
11. Weidong-Richard JI, Castelino FJ, Chang Y. Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. FASEB J 1998, 12:1731-8.
12. MacDonald NJ, Murad AC, Fogler WE, Lu Y, Sim BKL. The tumor-suppressing activity of angiostatin protein resides within kringles 1 to 3. Biochem Biophys Res Commun 1999, 264:469-77.
13. O'Reilly MS, Holmgren L, Shing Y. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastasis by a Lewis lung carcinoma. Cell 1994, 79:315-28.
14. Tschopp JF, Brust PF, Cregg JM, Stilmam CA, Gingeras TR. Expression of the LacZ gene from two methanol-regulated promoters in Pichia pastoris. Nucleic Acids Res 1987, 15:3859-76.
15. Duman JG, Miele RG, Liang H. Mannosylation of Pichia pastoris cellular and recombinant proteins. Biotechnol Appl Biochem 1998, 28:39-45.
16. Chen Y, Cino J, Hart G, Freedman D, White C, Komives EA. High protein expression in fermentation of recombinant Pichia pastoris by a fed-batch process. Proc Biochem 1997, 32:107-11.
17. Bailey PJ. Sponge implants as models. Methods Enzymol 1988, 162:327-34.
18. Hu DE, Hiley CR, Smither RL, Gresham GA, Fan TP. Correlation of 133Xe clearance, blood flow and histology in the rat sponge model for angiogenesis. Further studies with angiogenic modifiers. Lab Invest 1995, 72:601-10.
19. Machado RD, Santos RA, Andrade SP. Opposing actions of angiotensins on angiogenesis. Life Sci 2000, 66:67-76.
20. Gomes ML, Oliveira MBN, Bernardo-Filho M. Drug interaction with radiopharmaceuticals: effect on the labeling of red blood cells with technetium-99m and on the bioavailability of radiopharmaceuticals. Braz Arch Biotechnol 2002, 45:143-9.
21. Barcelos LS, Talvani A, Teixeira A. Impaired inflammatory angiogenesis, but not leukocyte influx, in mice lacking TNFR1. J Leuk Biol 2005, 78:352-8.
22. Folkman J. Tumor angiogenesis: therapeutics implications. N Engl J Med 1971, 285:1182-6.
23. Folkman J. A new family of mediators of tumor angiogenesis. Cancer Invest 2001, 19:754-5.
24. Shadi PK, Pineda IF. Tumoral angiogenesis: review of the literature. Cancer Invest 2008, 26:104-8.
25. Sim BKL, O'Reilly MS, Liang H. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 1997, 57:1329-34.
26. Zhang AL, Zhang TY, Luo JX. Constitutive expression of human angiostatin in Pichia pastoris by high-density cell culture. J Ind Microbiol Biotechnol 2006, 34:117-22.
27. Hayes M, Castellino FJ. Carbohydrate of the human plasminogen variants. III. Structure of the O-glycosidically linked oligosaccharide unit. J Biol Chem 1979, 254:8777-80.
28. Hayes M, Castellino FJ. Carbohydrate of the human plasminogen variants. II. Structure of the asparagine-linked oligosaccharide unit. J Biol Chem 1979, 254:8772-6.
29. Pirie-Shepherd SR, Stevens RD, Andon NL, Enghild JJ, Pizzo SV. Evidence for a novel O-linked sialylated trisaccharide on Ser-248 of human plasminogen 2. J Biol Chem 1997, 272:7408-11.
30. Lage AP, Andrade SP. Assessment of angiogenesis and tumor growth in conscious mice by a fluorimetric method. Microvasc Res 2000, 59:278-85.
31. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991, 67:1033-6.
32. Sunderkotter C, Goebeler M, Shultze-osthoff K, Bhardwaj R, Sorg C. Macrofhage-derived angiogenesis factors. Pharmacol Ther 1991, 51:195-216.
33. Blair JR, Meng H, Marchese MJ. Human mast cells stimulate vascular tube formation. J Clin Invest 1997, 99:2691-700.
34. Benelli R, Morini M, Carrozzino F. Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J 2002, 16:267-9.
35. Moser TL, Stack MS, Asplin I. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A 1999, 96:2811-6.
36. Troyanovsky B, Levchenko T, Mansson G, Matvijenko O, Holmgre L. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 2001, 152:1247-54.
37. Rofstad EK, Halsor EF. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanome xenografts. Cancer Res 2000, 60:4932-8.
38. Seftor REB, Seftor EA, Gehlsen KR. Role of the αvβ3 integrin in human melanoma cell invasion. Proc Natl Acad Sci U S A 1992, 89:1557-61.
39. Sarmishtha DE, Razorenova O, McCabe NP, O'Toole T, Jun Q, Byzova TV. VEGF-integrin interplay controls tumor growth and vascularization. Proc Natl Acad Sci U S A 2005, 102:7589-94.